446285-30-9

Upstream product

• 791053-66-2 (7-chloro-1H-pyrrolo[3,2-b]pyridin-3-yl)-oxo-acetic acid 
• 13754-38-6 N-Benzoylpiperazine 

Downstream Products

• 619331-02-1 1-(4-benzoylpiperazin-1-yl)-2-(7-[1,2,3]triazol-1-yl-1H-pyrrolo[3,2-b]pyridin-3-yl)ethane-1,2-dione 
• 1417340-00-1 C₂₆H₂₁N₇O₃ 
• 1417340-01-2 C₂₅H₂₀N₈O₃ 
• 1417339-94-6 C₂₁H₂₀N₄O₄ 
• 619330-99-3 1-(7-benzofuran-2-yl-1H-pyrrolo[3,2-b]pyridin-3-yl)-2-(4-benzoyl-piperazin-1-yl)-ethane-1,2-dione 
• 619330-98-2 5-{3-[2-(4-Benzoyl-piperazin-1-yl)-2-oxo-acetyl]-1H-pyrrolo[3,2-b]pyridin-7-yl}-2H-pyrazole-3-carboxylic acid ethyl ester 
• 446289-92-5 1-benzoyl-4-[(7-(thiazol-2-yl)-4-azaindol-3-yl)oxoacetyl]piperazine 
• 619331-00-9 1-benzoyl-4-[(7-(oxazol-2-yl)-4-azaindol-3-yl)oxoacetyl]piperazine 

Relevant academic research and scientific papers

Inhibitors of HIV-1 attachment. Part 10. the discovery and structure-activity relationships of 4-azaindole cores

A series of 4-azaindole oxoacetic acid piperazine benzamides was synthesized and evaluated in an effort to identify an oral HIV-1 attachment inhibitor with the potential to improve upon the pre-clinical profile of BMS-378806 (7), an initial clinical compound. Modifications at the 7-position of the 4-azaindole core modulated potency significantly and SAR showed that certain compounds with a 5-membered ring heteroaryl group at that position were the most potent. Four of the compounds with the best profiles were evaluated in a rat pharmacokinetic model and all had superior oral bioavailability and lower clearance when compared with 7.